Biograil APS
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2039
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 14, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,070,566 | Oral Delivery of Active Drug Substances In force · High confidence | In force | High confidence | |
| US 11,452,851 | Oral Delivery of Active Drug Substances In force · High confidence | In force | High confidence | |
| US 12,708,284 | Drug Delivery Device with Carrier and Insert In force · High confidence | In force | High confidence | |
| US 12,582,810 | Delivery Device for Oral Delivery of Drug Substances In force · High confidence | In force | High confidence | |
| US 12,521,537 | Oral Drug Delivery Device with Cover Release In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending